首页> 外文期刊>Therapeutic Drug Monitoring >Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation.
【24h】

Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation.

机译:肾脏移植后一年以上维持阶段的麦考酚酸前药浓度监测。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Routine therapeutic drug monitoring of mycophenolic acid (MPA) is generally performed using the area under the concentration-time curve from 0 to 12 hours (AUC0-12) with recommended values between 30 and 60 mug.h/mL. OBJECTIVE: The aim of this study was to examine whether the monitoring of the MPA predose concentration (C0) in patients who are stable for >1 year after renal transplantation was practical and to determine factors that cause MPA C0 variability among patients. METHODS: Eighty-six Japanese patients who had undergone renal transplantation and were taking tacrolimus and who had their MPA C0 analyzed >6 times by high-performance liquid chromatography for >1 year posttransplantation were enrolled. RESULTS: Recipients with MPA AUC0-12 levels<30 mug.h/mL on day 28 and 1 year after transplantation had an MPA C0 of <2.0 mug/mL, with a sensitivity of 90.9% and a specificity of 70.7%. There was no significant difference in the mean dose-adjusted MPA C0>1 year after transplantation between subjects with either the UGT (1A1, 1A9, and 2B7) or drug transporter (SLCO1B3, ABCC2, and ABCG2) genotypes. However, in a multiple regression analysis, the dose-adjusted mean MPA C0>1 year after transplantation was significantly associated with age (P=0.0035), creatinine clearance (P=0.0001), and the dose-adjusted MPA AUC0-12 at 1 year (P=0.0147). CONCLUSIONS: To keep the MPA AUC0-12>30 mug.h/mL, the plasma threshold for maintaining the MPA C0 with tacrolimus should be set >2.0 mug/mL as determined by high-performance liquid chromatography. For patients who are stable for >1 year after transplantation, continued monitoring of the MPA C0 using the same samples used to monitor the tacrolimus C0 and the additional assessment of the MPA AUC0-12 at the 1-year time point seem to be a viable option. If a change of the mycophenolate mofetil dose seems necessary based on the routine MPA C0 information, the determination of MPA AUC0-12 using a limited sampling strategy is recommended.
机译:背景:霉酚酸(MPA)的常规治疗药物监测通常使用浓度时间曲线下0至12小时的面积(AUC0-12)进行,推荐值在30至60 mug.h / mL之间。目的:本研究的目的是检查在肾移植后稳定> 1年的患者中监测MPA前剂量浓度(C0)是否可行,并确定引起患者MPA C0变异性的因素。方法:纳入了八十六名日本患者,这些患者接受了肾移植手术并正在接受他克莫司治疗,并且其MPA C0经高效液相色谱法分析了> 6年,移植后> 1年。结果:在移植后第28天和第1年,MPA AUC0-12水平<30 mug.h / mL的接受者的MPA C0 <2.0 mug / mL,敏感性为90.9%,特异性为70.7%。具有UGT(1A1、1A9和2B7)基因型或药物转运蛋白(SLCO1B3,ABCC2和ABCG2)基因型的受试者之间的平均剂量调整后MPA C0移植后1年无显着差异。但是,在多元回归分析中,移植后1年的经剂量调整的平均MPA C0与年龄(P = 0.0035),肌酐清除率(P = 0.0001)和经剂量调整的MPA AUC0-12为1显着相关。年(P = 0.0147)。结论:为保持MPA AUC0-12> 30 mug.h / mL,通过他克莫司维持MPA C0的血浆阈值应设置为> 2.0 mug / mL,这是通过高效液相色谱法测定的。对于在移植后稳定> 1年的患者,使用用于监测他克莫司C0的相同样品并在1年时间点对MPA AUC0-12进行额外评估来持续监测MPA C0似乎是可行的。选项。如果根据常规MPA C0信息似乎需要改变霉酚酸酯的剂量,则建议使用有限采样策略确定MPA AUC0-12。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号